ABSTRACT
Carriage of medicaments assigned in the forms of conventional dosage is restricted to the eye; moreover, favorable drug concentrations in the destination tissues are not kept up for an extended time spread given that the eyes are escorted via an inimitable anatomy, physiology and biochemistry. The clearcut aim of designing a therapeutic system is to attain a desirable concentration of a drug at the active site for the relevant duration. A successful design of a drugdelivery system, therefore, desires an integrated knowledge of the drug molecule and the restrictions offered by the ocular route of administration. In last decade, with the emergence of miscellaneous powerful and multifaceted medicinal substitutes, the assortment of traditional ophthalmic preparations has progressively developed; drawing out considerably apart from ordinary solutions, suspensions and ointments, presently comprises a diversity of drug administration formats. Present communication echoes miscellaneous barriers and successive blossoms in the field of ocular therapeutics.
ABSTRACT
Drug delivery in ocular therapeutics is a challenging problem and is a subject of interest to scientists working in the multidisciplinary areas pertaining to the eye. Most ocular diseases are treated by topical drug application in the form of solutions, suspensions and ointment. These conventional dosage forms suffer from the problems of poor ocular bioavailability, because of various anatomical and pathophysiological barriers prevailing in the eye. Various efforts in ocular drug delivery have been made to improve the bioavailability and to prolong the residence time of drugs applied topically onto the eye. The potential use of polymeric nanoparticles as drug carriers has led to the development of many different colloidal delivery vehicles. Indeed, the association of an active molecule to a nanocarrier allows the molecule to intimately interact with specific ocular structures, to overcome ocular barriers and to prolong its residence in the target tissue. This review discusses the physiochemical characterization, fabrication techniques, therapeutic significances, patented technology of Eudragit based nanoparticles and future possibility in the field of ocular drug delivery.